KẾT QUẢ KHÚC XẠ SAU 5 NĂM ĐIỀU TRỊ BỆNH VÕNG MẠC TRẺ ĐẺ NON BẰNG TIÊM BEVACIZUMAB NỘI NHÃN TẠI BỆNH VIỆN NHI TRUNG ƯƠNG

Abstract

Objective: Assessment of refractive outcomes five years post-treatment for retinopathy of prematurity with intraocular Bevacizumab injection at Viet Nam National Children’s Hospital. Discussion on related factors impacting refractive results. Materials and methods: the study was conducted on patients diagnosed with retinopathy of prematurity type 1 who underwent intravitreal Bevacizumab injection at the Department of Ophthalmology – National Children’s Hospital before February 2018. This retrospective cross-sectional descriptive study encompasses 224 eyes of 115 patients. Results: The mean spherical equivalent was -1.72 ± 4,17D. This encompassed 105 myopic eyes (47,2%), with an average myopia power was -3,69 ± 4,01D. Additionally, 30 eyes exhibited hyperopia (13,6%), with an average hyperopia power was + 2.08 ± 1,22D. Among these, 45 eyes were diagnosed with high myopia, representing 20,2% of the sample, while 7 eyes had high hyperopia, accounting for 3,2%. Conclusion: The prevalence of refractive errors among patients who had retinopathy of prematurity treated with intravitreal Bevacizumab injection is considerable, at 60,8%, with myopia being the majority, constituting 47,2% of cases. Furthermore, significant associations exist between the development of myopia and gestational age, birth weight, and disease severity. Recommendation: children who have undergone treatment for retinopathy of prematurity with intravitreal Bevacizumab injection need to have routine vision screening to promptly identify and manage refractive errors, thereby preventing the risk of amblyopia complication.